This is very interesting, Biotron seeking partners in China!...

This is very interesting, Biotron seeking partners in China! (and yes its FACT - not up-ramping)

On March 27, at the China-Australia Biotechnology Investment Conference co-hosted by AusBiotech (Australian Biomedical Association), MTP Connect, China Bluesky and Pfarrell, 14 Australian companies (including 5 listed companies and 7 biotechnology companies) Landed in China with original patents and technologies. As a media support, Shell Society visited the site in person and brought readers an outline of Australia's biotechnology investment.

Biotron Limited (ASX: BIT) is a listed biotechnology company based in Sydney, Australia, which develops new drugs for serious viral diseases. The company is developing and commercializing a new small molecule drug that treats multiple viral diseases. Scientists have discovered the virus protein of Viroporin in many viruses, and it is essential for the pathogenicity of the virus. The core technology of Biotron is to target attacks called viroporins. The company has developed a key library of viroporin inhibitors and screening assays for key viral targets.The company's main drug is BIT225, which focuses on HIV-1 and hepatitis C virus (HCV), and is currently in clinical phase II.In addition to its clinical development plan for BIT225, Biotron also has drug development plans for other viruses, including dengue and respiratory viruses, Ebola and Zika viruses. Biotron is seeking a partnership to further the clinical development of its projects, and is also collaborating on the commercialization of antiviral assets.

And from other articles in the past week -

"China’s venture capital funding rallies after coronavirus lockdown - March activity up sixfold to $2.5bn as investors seek bargains in biotech and education start-ups"

"China is set to become a more influential player in the world’s drug-making market as regulatory changes and a surge in investment in research triggered by the Covid-19 outbreak give the country an advantage over many other jurisdictions..."

In the next five years, I believe there will be a number of Chinese pharmaceutical firms joining the world’s top list,’

"In terms of fundraising in the pharmaceutical and biotech space, China raised US$16.5 billion through 90 deals last year, a 17 per cent increase in volume and 13 per cent increase in value from 2018, driven by heavy investment, particularly in research, according to a Baker Mckenzie report released in February."

Without an ANN, it's great news to confirm that at least we know they are active in seeking commercial partnerships (at least in China) and with the growth of the Pharma market and investment potential for China - may only be good new for Biotron !